Orthogon Therapeutics LLC, a Canton, Mass.-based drug development company focused on designing innovative antivirals and anti-infective therapeutics, raised an additional $8m funding round.
A syndicate of US based healthcare angels participated in the round, which brings the total investment to date to $12.5m.
The company intends to use the funds to advance its pipeline of first-in-class drug assets.
Led by Dr. Ali H. Munawar, CEO and former founding CEO of Novira Therapeutics, Orthogon Therapeutics aims to develop a safe and effective prophylactic and therapeutic option for transplant and immunocompromised patients at risk of developing BK virus associated complications and graft rejection. The company uses structure-based drug design and biophysics to optimize drugs that bind selectively and safely neutralize target proteins that have been considered difficult to “drug”.
The new round of funding will accelerate Orthogon’s preclinical drug candidate towards pre-IND studies and expand its anti-infective discovery pipeline.